Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Average Rating of “Buy” from Brokerages

Bicara Therapeutics Inc. (NASDAQ:BCAX) has been assigned an average recommendation of “Buy” from the eight analysts that are covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $41.20.

BCAX has been the topic of a number of research analyst reports. HC Wainwright boosted their price objective on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Wedbush reaffirmed an “outperform” rating and set a $31.00 price objective on shares of Bicara Therapeutics in a research report on Wednesday, February 12th.

Bicara Therapeutics Trading Down 7.2 %

Bicara Therapeutics stock opened at $15.36 on Tuesday. The stock has a 50 day moving average price of $13.49. Bicara Therapeutics has a fifty-two week low of $11.10 and a fifty-two week high of $28.09.

Institutional Trading of Bicara Therapeutics

Large investors have recently added to or reduced their stakes in the business. First Turn Management LLC bought a new stake in Bicara Therapeutics in the third quarter worth approximately $14,324,000. Geode Capital Management LLC bought a new stake in Bicara Therapeutics in the third quarter worth approximately $1,239,000. Vestal Point Capital LP bought a new stake in Bicara Therapeutics in the third quarter worth approximately $10,825,000. FMR LLC bought a new stake in Bicara Therapeutics in the third quarter worth approximately $57,913,000. Finally, Braidwell LP bought a new stake in Bicara Therapeutics in the third quarter worth approximately $42,219,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.